Targeted NGS Service
NGS Gene Panel Specifically Detects Actionable Mutations for Targeted Therapy
Minimum of three samples required
Covers 65 genes including major oncogenes and tumor suppressor genes
Less than 7-day turnaround time from FFPE/plasma sample to reporting
Cost-effective service with high quality testing and reliable results
Highly sensitive: as low as 1% variant allele frequency (VAF) detection
Low DNA input: 10ng for detection of somatic mutations
OptiSeq™ NGS Pan-Cancer Panel Service
A targeted cancer panel, especially an actionable gene panel, provide reference information and guidance for cancer therapies. Our pan-cancer gene panel includes sequencing information for more than 600 amplicons in 65 common oncogenes and tumor suppressor genes and identifies gene mutations with clinical significance under both research and CLIA lab environment.
OptiSeq™ Pan-Cancer Gene Panel (65 Genes)
| ABL1 | AKT1 | ALK | APC | ATM | BRAF | BRCA1 |
|---|---|---|---|---|---|---|
| BRCA2 | CDH1 | CDKN2A | CSF1R | CTNNB1 | DDR2 | DNMT3A |
| EGFR | ERBB2 | ERBB3 | ERBB4 | EZH2 | FBXW7 | FGFR1 |
| FGFR2 | FGFR3 | FLT3 | FOXL2 | GNA11 | GNAQ | GNAS |
| HNF1A | HRAS | IDH1 | IDH2 | JAK2 | JAK3 | KDR |
| KIT | KRAS | MAP2K1 | MET | MLH1 | MPL | MSH6 |
| MTOR | NF1 | NF2 | NOTCH1 | NPM1 | NRAS | PDGFRA |
| PIK3CA | PIK3R1 | PTCH1 | PTEN | PTPN11 | RB1 | RET |
| SMAD4 | SMARCB1 | SMO | SRC | STK11 | TERT | TP53 |
| TSC1 | VHL |
Need Help?
